Skip to main content
SpringerLink
Log in

Adjuvant chemotherapy in colorectal carcinoma

Results of a meta-analysis

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

Despite the National Institutes of Health consensus regarding use of adjuvant chemotherapy in colorectal carcinoma, many general surgeons question the efficacy of this approach when considering costs involved for both the individual patient and society at large. PURPOSE: This study was designed to determine the real impact of adjuvant chemotherapy on five-year survival rates of patients. METHOD: A qualitative and quantitative meta-analysis of results from 39 randomized clinical trials published from 1959 to 1993 is described. RESULTS: Design quality of clinical trials had a mean score of 48.6 percent (±6.2 standard deviation). A small benefit of therapy in terms of overall survival was noted, with a mortality odds ratio (OR) of 0.91 (confidence interval (CI) 95 percent, 0.83–0.99). For the group of colon carcinomas, the OR was 0.81 (CI 95 percent, 0.69–0.94) with an OR of 0.64 (CI 95 percent, 0.48–0.85) for the group of rectal carcinomas. The effect size was 0.09 for the colon group and 0.20 for the rectal group. For those patients who receive chemotherapy, this effect size implies that we can expect an increase of 5 percent in the survival rate in the group with colon carcinoma and a 9 percent increase in the survival rate in the group with rectal carcinoma. CONCLUSION: Given the high incidence of colorectal carcinoma, the small benefit observed for those patients receiving chemotherapy is far from negligible. However, indications for adjuvant chemotherapy warrant further discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Willet CG, Tepper JE, Cohen AM. Failure patterns following curative resection of colonic carcinoma. Ann Surg 1984;200:685–92.

    PubMed  Google Scholar 

  2. Lopez M. Adjuvant therapy of colorectal cancer. Dis Colon Rectum 1994;37(Suppl):S86–91.

    PubMed  Google Scholar 

  3. Levitan N. Chemotherapy in colorectal carcinoma. Surg Clin North Am 1993;73:183–98.

    PubMed  Google Scholar 

  4. Adjuvant therapy for patients with colon and rectum cancer. NIH Consensus Dev Conf Consens Statement 1990;Apr 16–18(4).

  5. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988;259:3571–8.

    PubMed  Google Scholar 

  6. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Chimiothérapie adjuvante du cancer colorectal: qu'apprendre d'une méta-analyse? Bull Cancer (Paris) 1989;76:1021–8.

    Google Scholar 

  7. Bruckner HW. Adjuvant chemotherapy in colorectal cancer: mournful, hopeful perpetual motion machine heads to dim light at end of tunnel [letter]. JAMA 1989;261:987.

    PubMed  Google Scholar 

  8. Clouse LH. Adjuvant chemotherapy in colorectal cancer: mournful, hopeful perpetual motion machine heads to dim light at end of tunnel [letter]. JAMA 1989;261:987–8.

    PubMed  Google Scholar 

  9. Chalmers TC, Smith H, Blackburn B,et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981;2:31–49.

    PubMed  Google Scholar 

  10. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991;44:127–39.

    PubMed  Google Scholar 

  11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.

    PubMed  Google Scholar 

  12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177–88.

    PubMed  Google Scholar 

  13. Veterans Administration Adjuvant Cancer Chemotherapy Cooperative Group. The use of 5-fluordeoxyuridine (FUDR) as a surgical adjuvant in carcinoma of the stomach and colorectum. Arch Surg 1963;86:926–31.

    Google Scholar 

  14. Dwight R. Adjuvant chemotherapy in cancer of the large bowel: an interim report of the Veterans Administration surgical adjuvant cancer chemotherapy study. Am J Surg 1964;107:609–13.

    PubMed  Google Scholar 

  15. Higgins GA, Dwight RW, Smith JV, Keehn RJ. Fluorouracil as an adjuvant to surgery in carcinoma of the colon. Arch Surg 1971;102:339–43.

    PubMed  Google Scholar 

  16. Rousselot LM, Cole DR, Grossi CE, Conte AJ, Gonzalez EM, Pasternack BS. Adjuvant chemotherapy with 5-fluorouracil in surgery for colorectal cancer: eight-year progress report. Dis Colon Rectum 1972;15:169–74.

    PubMed  Google Scholar 

  17. Verhaegen H, De Cree J, De Cock W, Verhaegen-Declerq ML, Verbruggen F. Levamisole therapy in patients with colorectal cancer. In: Rosenberg TW, ed. Immunotherapy of human cancer. New York: Elsevier Science, 1982:225–9.

    Google Scholar 

  18. Higgins GA, Donaldson RC, Rogers LS, Juler GL, Keehn RJ. Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 1984;54:193–8.

    PubMed  Google Scholar 

  19. Boulis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Cancer 1984;54:1811–8.

    Google Scholar 

  20. Sparso BH, Von der Maase H, Kristensen D,et al. Complications following postoperative combined radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid: a randomized trial that failed. Cancer 1984;54:2363–6.

    PubMed  Google Scholar 

  21. Chlebowski RT, Nystrom S, Reynolds R, Weiner JM, Bateman JR. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial. Oncology 1988;45:141–3.

    PubMed  Google Scholar 

  22. Zaniboni A, Erlichman C, Seitz JF,et al. FUFA increases disease-free survival in resected B2C colon cancer: results of a pooled analysis of 3 randomised trials [abstract]. Proc Am Soc Clin Oncol 1993;12:191.

    Google Scholar 

  23. Mrazek R, Economou S, McDonald GO, Slaughter DP, Cole WH. Prophylactic and adjuvant use of nitrogen mustard in the surgical traitment of cancer. Ann Surg 1959;150:745–55.

    PubMed  Google Scholar 

  24. Dwight RW, Higgins GA, Keehn RJ. Factors influencing survival after resection in cancer of the colon and rectum. Am J Surg 1969;117:512–22.

    PubMed  Google Scholar 

  25. Dixon WJ, Longmire WP Jr, Holden WD. Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten-year follow-up. Ann Surg 1971;173:26–39.

    PubMed  Google Scholar 

  26. Dwight RW, Humphrey EW, Higgings GA, Keehn RJ. FUDR as an adjuvant to surgery in cancer of the large bowel. J Surg Oncol 1973;5:243–9.

    PubMed  Google Scholar 

  27. Higgins GA, Humphrey EW, Juler G, LeVeen HH, Mc-Caughan J, Keehn RJ. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. (a) Cancer 1976;38:1461–7.

    PubMed  Google Scholar 

  28. Higgins GA, Humphrey EW, Juler G, LeVeen HH, Mc-Caughan J, Keehn RJ. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. (b) Cancer 1976;38:1461–7.

    PubMed  Google Scholar 

  29. Grossi CE, Wolff WI, Nealon TF Jr, Pasternack B, Ginzburg L, Rousselot LM. Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for resectable carcinoma of the colon and rectum. Surg Gynecol Obstet 1977;145:549–54.

    PubMed  Google Scholar 

  30. Higgings GA Jr, Lee LE Jr, Dwight RW, Keehn RJ. The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clin Trials 1978;1:35–41.

    Google Scholar 

  31. Lawrence W Jr, Terz JJ, Horsley JS 3d, Brown PW, Romero C. Chemotherapy as an adjuvant to surgery for colorectal cancer: a follow-up report. Arch Surg 1978;113:164–8.

    PubMed  Google Scholar 

  32. Bancewicz J, Calman KC, Macpherson SG, McArdle SC, McVie JG, Soukop M. Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication. J R Soc Med 1980;73:197–9.

    PubMed  Google Scholar 

  33. Grage TB, Moss SE. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial. Surg Clin North Am 1981;61:1321–9.

    PubMed  Google Scholar 

  34. Higgings GA Jr, Amadeo JH, McElhinney J, McCaughan JJ, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel: a Veterans Administration Surgical Oncology Group report. Cancer 1984;53:1–8.

    PubMed  Google Scholar 

  35. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 1984;310:737–43.

    Google Scholar 

  36. Hafstrom L, Rudenstam CM, Domellof L. A randomized trial of oral 5-fluorouracilversus placebo as adjuvant therapy in colorectal cancer Astler-Coller Dukes' B and C: results after 5 years observation time. Br J Surg 1985;72:138–41.

    PubMed  Google Scholar 

  37. Wunderlich M, Schiessel R, Rainer H,et al. Effect of adjuvant chemo or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg 1985;72(Suppl.):S107–10.

    PubMed  Google Scholar 

  38. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1985;312:1465–72.

    Google Scholar 

  39. Gilbert JM, Hellmann K, Evans M,et al. Randomized trial of oral adjuvant razoxane (ICRF-159) in resectable colorectal cancer: five-year follow-up. Br J Surg 1986;73:446–50.

    PubMed  Google Scholar 

  40. Irvin T, Vowles KD, Golby MG. Fluorouracil in chemoprophylaxis of colorectal cancer: results of a controlled clinical trial. Dis Colon Rectum 1986;29:704–6.

    PubMed  Google Scholar 

  41. Windle R, Bell PR, Shaw D. Five-year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569–72.

    PubMed  Google Scholar 

  42. Wolmark N, Fisher B, Rockette H, and other NSABP Investigators. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30–6.

    PubMed  Google Scholar 

  43. Fisher B, Wolmark N, Rockette H, and other NSABP Investigators. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21–9.

    PubMed  Google Scholar 

  44. Panettiere FJ, Goodman PJ, Costanzi JJ,et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol 1988;6:947–54.

    PubMed  Google Scholar 

  45. Arnaud JP, Buyse M, Nordlinger B,et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg 1989;76:284–9.

    PubMed  Google Scholar 

  46. Laurie JA, Moertel CG, Fleming TR,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447–56.

    PubMed  Google Scholar 

  47. Moertel CG, Fleming TR, MacDonald JS,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.

    PubMed  Google Scholar 

  48. Krook JE, Moertel CG, Gunderson LL,et al. Effective surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 1991;324:709–15.

    PubMed  Google Scholar 

  49. Wolmark N, Rockette H, Fisher B,et al. Leucovorinmodulated 5-FU (LV-FU) as adjuvant therapy for primary colon cancer [abstract]. NSABP C-03. Proc Am Soc Clin Oncol 1993;12:197.

    Google Scholar 

  50. Kingston RD, Fielding JW, Palmer MR. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colo-rectal cancer: report of a controlled randomised study of 603 patients. Int J Colorectal Dis 1993;8:106–10.

    PubMed  Google Scholar 

  51. O'Connell M, Mailliard J, MacDonald J, Haller D, Mayer R, Wieand H. An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer [abstract]. Proc Am Soc Clin Oncol 1993;12:190.

    Google Scholar 

  52. Jenicek M. Meta-analysis in medecine: where we are and where we want to go. J Clin Epidemiol 1989;42:35–44.

    PubMed  Google Scholar 

  53. Macfarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457–60.

    PubMed  Google Scholar 

  54. Philips RY, Hittinger R, Blesouwsky L, Fry JS, Fielding LL. Local recurrence following curative surgery for large bowel cancer. I. The overall picture. Br J Surg 1984;71:12–6.

    PubMed  Google Scholar 

  55. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Ilstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994;220:676–82.

    PubMed  Google Scholar 

  56. Chlebowski RT, Lillington L, Nystrom JS, Sayre J. Late mortality and levamisole adjuvant therapy in colorectal cancer. Br J Cancer 1994;69:1094–7.

    PubMed  Google Scholar 

  57. Moertel CG, Fleming TR, Macdonald JS,et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321–6.

    PubMed  Google Scholar 

  58. Borza KS, Bidker PM. Discordance between metaanalysis and large-scale randomized controlled trials. Ann Intern Med 1995;123:873–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Montreal, Montreal, Quebec, Canada

    S. Dubé M.D., M.Sc. & F. Heyen M.D.

  2. Social and Preventive Medicine Faculty of Medecine, University of Montreal, Montreal, Quebec, Canada

    M. Jenicek M.D., Ph.D.

Authors
  1. S. Dubé M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Heyen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Jenicek M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Read at the meeting of The American Society of Colon and Rectal Surgeons, Montreal, Quebec, Canada, May 7 to 12, 1995.

About this article

Cite this article

Dubé, S., Heyen, F. & Jenicek, M. Adjuvant chemotherapy in colorectal carcinoma. Dis Colon Rectum 40, 35–41 (1997). https://doi.org/10.1007/BF02055679

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02055679

Key words

Search

Navigation